Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN.

Hormones (Athens). 2017 Jul;16(3):306-312. doi: 10.1007/BF03401525. Epub 2017 Nov 30.

PMID:
30091117
2.

An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN.

Hormones (Athens). 2017 Jul;16(3):200-204. doi: 10.14310/horm.2002.1749.

3.

Five gene variants in nonagenarians, centenarians and average individuals.

Kolovou V, Bilianou H, Giannakopoulou V, Kalogeropoulos P, Mihas C, Kouris M, Cokkinos DV, Boutsikou M, Hoursalas I, Mavrogeni S, Katsiki N, Kolovou G.

Arch Med Sci. 2017 Aug;13(5):1130-1141. doi: 10.5114/aoms.2017.68942. Epub 2017 Aug 3.

4.

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.

Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.

Metabolism. 2017 Jun;71:17-32. doi: 10.1016/j.metabol.2017.02.014. Epub 2017 Mar 4. Review.

PMID:
28521870
5.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

6.

L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.

Florentin M, Elisaf MS, Rizos CV, Nikolaou V, Bilianou E, Pitsavos C, Liberopoulos EN.

Lipids. 2017 Jan;52(1):1-9. doi: 10.1007/s11745-016-4216-z. Epub 2016 Dec 2.

PMID:
27914033
7.

Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Achimastos A, Alexandrides T, Alexopoulos D, Athyros V, Bargiota A, Bilianou E, Chrysochoou C, Drogari E, Elisaf M, Ganotakis E, Goudevenos I, Ioannidis I, Kolovou G, Kotsis V, Lekakis I, Liberopoulos E, Melidonis A, Nikolaou V, Ntaios G, Papanas N, Pappas S, Pitsavos C, Rallidis L, Richter D, Skoumas I, Tentolouris N, Tousoulis D, Tselepis A, Tsioufis K, Tziakas D, Tziomalos K, Vardas P, Vlachopoulos C, Vlahakos D.

Hormones (Athens). 2016 Jan-Mar;15(1):8-14. doi: 10.14310/horm.2002.1659.

8.

The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice.

Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Ceška R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, da Silva PM, Masana L, Odawara M, Pedersen TR, Rotella CM, Salti I, Teramoto T, Tokgozoglu L, Toth PP, Valensi P, Vergès B.

Atheroscler Suppl. 2014 Jun;15(1):1-15. doi: 10.1016/j.atherosclerosissup.2014.04.001. Review.

9.

Ageing mechanisms and associated lipid changes.

Kolovou G, Katsiki N, Pavlidis A, Bilianou H, Goumas G, Mikhailidis DP.

Curr Vasc Pharmacol. 2014;12(5):682-9. Review.

PMID:
24350931
10.

The challenges in moving from ageing to successful longevity.

Kolovou G, Barzilai N, Caruso C, Sikora E, Capri M, Tzanetakou IP, Bilianou H, Avery P, Katsiki N, Panotopoulos G, Franceschi C, Benetos A, Mikhailidis DP.

Curr Vasc Pharmacol. 2014;12(5):662-73. Review.

PMID:
24350930
11.

Ageing, longevity, exceptional longevity and related genetic and non genetics markers: panel statement.

Avery P, Barzilai N, Benetos A, Bilianou H, Capri M, Caruso C, Franceschi C, Katsiki N, Mikhailidis DP, Panotopoulos G, Sikora E, Tzanetakou IP, Kolovou G.

Curr Vasc Pharmacol. 2014;12(5):659-61.

PMID:
24350929
12.

Task force on: 'Early markers of atherosclerosis: influence of age and sex'.

Ciccone MM, Bilianou E, Balbarini A, Gesualdo M, Ghiadoni L, Metra M, Palmiero P, Pedrinelli R, Salvetti M, Scicchitano P, Zito A, Novo S, Mattioli AV.

J Cardiovasc Med (Hagerstown). 2013 Oct;14(10):757-66. doi: 10.2459/JCM.0b013e328362078d. Review.

PMID:
24335886
13.

The frequency of 4 common gene polymorphisms in nonagenarians, centenarians, and average life span individuals.

Kolovou G, Kolovou V, Vasiliadis I, Giannakopoulou V, Mihas C, Bilianou H, Kollia A, Papadopoulou E, Marvaki A, Goumas G, Kalogeropoulos P, Limperi S, Katsiki N, Mavrogeni S.

Angiology. 2014 Mar;65(3):210-5. doi: 10.1177/0003319712475075. Epub 2013 Feb 6.

PMID:
23389097
14.

Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience).

Kolovou G, Hatzigeorgiou G, Mihas C, Gontoras N, Litras P, Devekousos D, Kontodima P, Sorontila C, Bilianou H, Mavrogeni S.

Cholesterol. 2012;2012:976578. doi: 10.1155/2012/976578. Epub 2012 Jan 24.

15.

One more look at guidelines for primary and secondary prevention of cardiovascular disease in women.

Kolovou G, Marvaki A, Bilianou H.

Arch Med Sci. 2011 Oct;7(5):747-55. doi: 10.5114/aoms.2011.25547. Epub 2011 Nov 8.

16.

Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.

Athyros VG, Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group.

Angiology. 2012 Jul;63(5):358-66. doi: 10.1177/0003319711421341. Epub 2011 Oct 17.

PMID:
22007026
17.

The role of common variants of the cholesteryl ester transfer protein gene in left main coronary artery disease.

Kolovou G, Vasiliadis I, Kolovou V, Karakosta A, Mavrogeni S, Papadopoulou E, Papamentzelopoulos S, Giannakopoulou V, Marvaki A, Degiannis D, Bilianou H.

Lipids Health Dis. 2011 Sep 7;10:156. doi: 10.1186/1476-511X-10-156.

18.

Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.

Athyros VG, Karagiannis A, Ganotakis ES, Paletas K, Nicolaou V, Bacharoudis G, Tziomalos K, Alexandrides T, Liberopoulos EN, Mikhailidis DP; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group.

Curr Med Res Opin. 2011 Aug;27(8):1659-68. doi: 10.1185/03007995.2011.595782. Epub 2011 Jun 30.

PMID:
21714711
19.

Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.

Athyros VG, Ganotakis E, Kolovou GD, Nicolaou V, Achimastos A, Bilianou E, Alexandrides T, Karagiannis A, Paletas K, Liberopoulos EN, Tziomalos K, Petridis D, Kakafika A, Elisaf MS, Mikhailidis DP; Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative.

Curr Vasc Pharmacol. 2011 Nov;9(6):647-57.

PMID:
21476961
20.

Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement.

Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G.

Curr Vasc Pharmacol. 2011 May;9(3):258-70. Review.

PMID:
21314632

Supplemental Content

Loading ...
Support Center